BIRMINGHAM, Ala.–(BUSINESS WIRE)–ProAssurance Corporation (NYSE:PRA) will report results for the quarter ended June 30, 2019 after the close of normal New York Stock Exchange trading on Wednesday, August 7, 2019.
ProAssurance will conduct a conference call at 10:00 am et on Thursday, August 8, 2019 to discuss the results, and other items of interest to investors participating in the call. US-based investors are invited to participate by phone by dialing (888) 349-0134 (toll free), Canadian investors may dial (855) 669-9657 (toll free), and international investors may dial (412) 317-5145. The conference call will also be webcast through the Investor Relations section of ProAssurance.com.
A telephone replay of the call will be available through at least October 31, 2019 using access code 10133041. Investors in the United States may dial (877) 344-7529 (toll free), Canadian investors may dial (855) 669-9658 (toll free), and international investors may dial (412) 317-0088. A replay will be available on the internet through at least June 30, 2020 at ProAssurance.com. ProAssurance will make a podcast of the call available on its website and on iTunes.
About ProAssurance
ProAssurance Corporation is an industry-leading specialty insurer with extensive expertise in healthcare professional liability, products liability for medical technology and life sciences, legal professional liability, and workers’ compensation insurance. The company is recognized as one of the top performing insurance companies in America by virtue of our inclusion in the Ward’s 50 for the past twelve years. ProAssurance Group is rated “A+” (Superior) by A.M. Best; ProAssurance and its operating subsidiaries are rated “A” (Strong) by Fitch Ratings.
For the latest on ProAssurance and its industry leading suite of products and services, cutting edge risk management and practice enhancement programs follow @ProAssurance on Twitter or LinkedIn. ProAssurance’s YouTube channel regularly presents thought provoking, insightful videos that communicate effective practice management, patient safety and risk management strategies.
Contacts
Ken McEwen, Investor Relations Manager
800-282-6242 • 205-439-7903 • KenMcEwen@ProAssurance.com
--Data presented at the American College of Cardiology Annual Scientific Session show that the reduction…
Discover the Oral Probiotic That’s Reshaping Dental Health—Backed by 75,000+ Users and Groundbreaking Science ProDentim…
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2…
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted…
NeuroQuiet Reviews NeuroQuiet VANCOUVER, WA, March 29, 2025 (GLOBE NEWSWIRE) -- NeuroQuiet Reviews In a…
Ozempic® improved maximum walking distance by 13% vs placebo in adults with type 2 diabetes…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="600px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
